VALCYTE for ORAL SOLUTION

Compare VALCYTE for ORAL SOLUTION  to:
Compare
Compare

Generic Name for VALCYTE for ORAL SOLUTION

Valganciclovir (as HCl) (prodrug of ganciclovir) 50mg/mL; pwd for reconstitution; tutti-frutti flavor.

Legal Classification:

Rx

Pharmacological Class for VALCYTE for ORAL SOLUTION

Nucleoside analogue.

Manufacturer of VALCYTE for ORAL SOLUTION

Roche Laboratories

Indications for VALCYTE for ORAL SOLUTION

Prevention of CMV disease in kidney and heart transplant pediatric patients (4 months to 16 years old) at high risk.

Adult dose for VALCYTE for ORAL SOLUTION

Use tablet form.

Children's dosing for VALCYTE for ORAL SOLUTION

<4months: not recommended. Take with food. ≥4months: Dose (mg)= 7 x BSA x Creatinine Clearance (see literature). Round calculated dose to the nearest 25mg increment; max 900mg.

Also:

Contraindications for VALCYTE for ORAL SOLUTION

Acyclovir or ganciclovir allergy.

Precautions for VALCYTE for ORAL SOLUTION

Do not substitute on a mg-per-mg basis for ganciclovir. Avoid handling broken tabs. Withhold dose if absolute neutrophil count <500 cells/microliter, platelet count <25,000/microliter, or hemoglobin <8 g/dL. Reduce dose or discontinue if blood dyscrasias occur. Renal impairment. Cytopenia or cytopenic reactions to drugs, chemicals, irradiation. Monitor CBCs, platelets, ophthalmic, and renal function. Maintain adequate hydration. Use effective contraception during (men and women) and for at least 90 days after treatment (men). Elderly. Pregnancy (Cat.C: teratogenic, embryotoxic, carcinogenic, aspermatogenesis in animals), nursing mothers: see literature.

Interactions for VALCYTE for ORAL SOLUTION

Zidovudine increases anemia/neutropenia risk. Caution with nephrotoxic drugs (eg, cyclosporine, amphotericin B, mycophenolate). Monitor for toxicity with didanosine. Probenecid increases levels. Caution with drugs that inhibit replication of rapidly-dividing cells (eg, dapsone, pentamidine, antineoplastics). Avoid imipenem-cilastatin (seizures).

Adverse Reactions for VALCYTE for ORAL SOLUTION

GI upset, fever, bone marrow depression, headache, insomnia, retinal detachment, peripheral neuropathy, paresthesia, aplastic anemia, bleeding, CNS effects, elevated serum creatinine, infections, tremor, hypertension.

How is VALCYTE for ORAL SOLUTION supplied?

Tabs—60
Soln—100mL (after constitution); available soon

Related Disease:

Cytomegalovirus

Related Resources

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).